Clinical-stage biotech Cybin Inc. (NYSE: CYBN) reported a net loss of $10.5 million for its fiscal third quarter ending Dec. 31, but highlighted progress in its lead drug development programs targeting major depressive disorder and anxiety.
The quarterly loss narrowed significantly from $30.3 million in the same period last year. Research…
Please login to read all 315 words.
